SCRI, Yale Cancer Center and Smilow Cancer Hospital Announce Scientific Collaboration to Advance Cancer Research

SCRI, Yale Cancer Center and Smilow Cancer Hospital Announce Scientific Collaboration to Advance Cancer Research

NASHVILLE, Tenn., May 30, 2012 (BUSINESS WIRE) -- Sarah Cannon Research Institute (SCRI). today announced the finalization of an agreement to collaborate scientifically with Yale Cancer Center (YCC) and Smilow Cancer Hospital at Yale-New Haven (SCH) to advance cancer research.

"The integration of SCRI's broad clinical trial knowledge with Yale's translational and drug discovery expertise makes for a unique collaboration unrivaled in the field of cancer research," said SCRI Chief Executive Officer Dee Anna Smith.

"This collaboration allows top scientific thought leaders in cancer to come together to develop enhanced clinical trial opportunities and increase access for patients to the latest treatments available," said Dr. Howard "Skip" A. Burris III, chief medical officer and executive director of drug development for SCRI.

As part of the collaboration, SCRI physician scientists will partner with physician scientists from Yale Cancer Center to discuss strategic scientific priorities and develop clinical research protocols.

Other components of the partnership include the opening of a clinical trial management office on the Yale Cancer Center campus in New Haven, CT and for Smilow Cancer Hospital to develop a network of community-based sites that will participate in the program. SCRI's role in the management of the clinical trials office will be to provide assistance in opening research studies at Yale and within their community network, as well as to augment clinical trial availability and participation of patients in Yale's service area.

"Our collaboration with SCRI, one of the world's premier research organizations focused on cancer therapies and drug development, will expand Yale's renowned experience in cancer innovation and provide our patients access to the newest cancer therapies available," said Dr. Thomas Lynch, Jr., director of YCC and physician-in-chief of Smilow Cancer Hospital at Yale-New Haven. "This collaboration is an example of how three leading, research-driven organizations can build on their strengths and work together to quickly bring new discoveries to our clinics and benefit cancer patients."

SCRI offers a robust clinical research infrastructure, an expansive strategic investigator site network and a drug development program that has conducted over 100 first-in-man trials. YCC is a National Cancer Institute-designated comprehensive cancer center with a strong background in drug discovery, molecular profiling, and translational research through clinical care at Smilow Cancer Hospital.

To learn more about SCRI, YCC, and SCH -- including ongoing research and clinical trials -- visit and and .

About SCRI

SCRI is a global strategic research organization focusing on advancing therapies and accelerating drug development. It is one of the largest clinical research programs, conducting community-based clinical trials in oncology and cardiology through affiliations with a network of hundreds of physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory and other research support services to drug development sponsors and strategic investigator sites.

About YCC

YCC is one of a select network of 41 comprehensive cancer centers in the country designated by the National Cancer Institute and the only one in Southern New England. Bringing together the resources of Yale-New Haven Hospital and Yale School of Medicine, its mission encompasses patient care, research, cancer prevention and control, community outreach and education.

About SCH

Smilow Cancer Hospital at Yale-New Haven is part of Yale-New Haven Hospital and is affiliated with Yale Cancer Center. Smilow Cancer Hospital, the most comprehensive cancer facility in New England, is a 14-story, 500,000-square-foot cancer hospital, which includes: 168 private inpatient rooms, outpatient multidisciplinary treatment centers, 12 operating rooms, infusion suites, diagnostic imaging services, a floor for children with cancer, a specialized women's cancer center and diagnostic and therapeutic radiology services for children and adults.

SOURCE: Sarah Cannon Research Institute (SCRI)


        Sarah Cannon Research Institute (SCRI)
        Lisa Morrissey, 615-483-3779
        [email protected]

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.